Oral immunotherapy with short ragweed extract in a novel encapsulated preparation: A double-blind study

Journal of Allergy and Clinical Immunology

Volumn 100, Issue 1, 1997, Pages 30-38

  Litwin, Allen ^a   Flanagan, Michael ^a   Entis, Gregory ^a   Gottschlich, Gregory ^a   Esch, Robert ^b   Gartside, Peter ^a   Michael, J Gabriel ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b Greer Laboratories Inc   (United States)

Author keywords

Immunotherapy; Microencapsulation; Nasal IgA antibodies; Oral immunotherapy; Short ragweed

Indexed keywords

ADULT; ALLERGY; ANTIGEN PRESENTATION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HAY FEVER; HUMAN; IMMUNOGENICITY; IMMUNOTHERAPY; PRIORITY JOURNAL; RAGWEED;

EID: 0030839694     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-6749(97)70191-X     Document Type: Article

References (49)

1. Frankland AW, Augustin R. Prophylaxis of summer hay-fever and asthma: a controlled trial comparing crude grass-pollen extracts with the isolated main protein component Lancet 1954;1:1055-7.
2. Lowell FC, Franklin W. A 'double-blind' study of treatment with aqueous allergenic extracts in cases of allergic rhinitis. J Allergy 1963;34:165-82.
3. Van Metre TE Jr, Marsh DG, Adkinson NF Jr, Kagey-Sobotka A, Khattiguabong A, Norman PS Jr, et al. Immunotherapy for cat asthma J Allergy Clin Immunol 1988;82:1055-67.
4. Hunt KJ, Valentine MD, Sobotka A, Benton AW, Amodio FJ, Lichtenstein LM. A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med 1978;299:257-61.
5. Taudorf E, Laursen LC, Lanner A, Björksten B, Dreborg S, Søborg M, et al. Oral immunotherapy in birch pollen hay fever. J Allergy Clin Immunol 1987;80:153-61.
6. Creticos PS, Nuclerio KM, Adkinson NF Jr, Norman PS. Efficacy, safety, and kinetics of oral ragweed immunotherapy in the treatment of allergic seasonal rhinitis [abstract]. J Allergy Clin Immunol 1990;85:165.
7. Van Niekerk CH, Wet JLD. Efficacy of grass-maize pollen oral immunotherapy in patients with seasonal hay-fever: a double-blind study. Clin Allergy 1987;17:507-13.
8. Mosbech H, Dreborg S, Madsen F, Ohlsson H, Stahl Skov P, Tandorf E, et al. High dose grass pollen tablets used for hyposensitization in hay-fever patients. A one-year double blind placebocontrolled study. Allergy 1987;42:451-5.
9. Urbanek R, Burgelin KH, Kahle S, Kuhn W, Wahn U. Oral immunotherapy with grass pollen in enterosoluble capsules. A prospective study of the clinical and immunological response. Eur J Pediatr 1990;149:545-50.
10. Oppenheimer J, Areson JG, Nelson HS. Safety and efficacy of oral immunotherapy with standardized cat extract. J Allergy Clin Immunol 1994;93:61-7.
11. Michael JG. The role of digestive enzymes in orally induced immune tolerance. Immunol Invest 1989;18:1049-54.
12. Jain SL, Michael JG. The influence of antigen digestion on orally induced immunity and tolerance. In: Mestecky J, Russel MW, Jackson S, Michalek SM, Tlaskalova-Hogenova H, Sterzl J, editors. Advances in mucosal immunology, part B. New York: Plenum Press; 1995. p. 1245-50.
13. Pesce AJ, Freisheim JM, Litwin A, Michael JG. Modulation of the immune response to allergens: phospholipase A degradation products suppress IgG and IgE response in mice. Int Arch Allergy Appl Immunol 1990;2:88-93.
14. Ferguson T, Peters T Jr, Reed R, Pesce AJ, Michael JG. Immunoregulatory properties of antigenic fragments from bovine serum albumin. Cell Immunol 1983;78:1-11.
15. Zhang Z, Apple RJ, Pesce A, Michael JG. Peptic fragments of bovine serum albumin bind antigen-specific T suppressor cells from orally tolerized mice. Cell Immunol 1987;104:426-33.
16. Jain SL, Barone S, Michael JG. Activation patterns of murine T cells after oral administration of an enterocoated soluble antigen. Cell Immunol 1996;167:170-5.
17. Jain SL, Barone S, Flanagan MP. Michael JG. Activation patterns of murine B cells after oral administration of an encapsulated soluble antigea Vaccine 1996;14:42-8.
18. Flanagan MF, Wang C, Michael JG. Characterization of the immune response following the oral administration of modified antigen in an adjuvant-free system [abstract]. J Immunol 1993:150:35.
19. Litwin A, Flanagan M, Entis G, Esch K, Gartside P, Michael JG. Immunologic effects of encapsulated short ragweed extract: a potent new agent for oral immunotherapy. Ann Allergy Asthma Immunol 1996;77:132-8.
20. Norman PS, Lichtenstein LM, Ishizaka K. Diagnostic tests in ragweed hayfever: a comparison of direct skin tests, IgE antibody measurements and basophil histamine release. J Allergy 1973;52:210-24.
21. Litwin A, Pesce AJ, Fischer T, Michael M, Michael JG. Regulation of the human immune response to ragweed pollen by immunotherapy. A controlled trial comparing the effect of immunosuppressive peptic fragments of short ragweed with standard treatment Clin Exp Allergy 1991;21:457-65.
22. Peng Z, Naclerio RM. Norman PS, Adkinson NF Jr. Quantitative IgE and IgG subclass responses during and after long-term ragweed immunotherapy. J Allergy Clin Immunol 1992;89:519-29.
23. Halpern GM, Gershwin LT, Gonzales G, Fowler ME. Diagnosis of inhalent allergy in a chimpanzee using "in vivo" and "in vitro" tests. Allergol Immunopathol 1989;17:271-6.
24. De Fillip J, Yman L, Schröder H. Clinical accuracy of updated version of Phadebas RAST test Ann Allergy 1981;45:249-55.
25. Elson C, Ealding N, Lefkowitz J. A lavage technique allowing repeated measurements if IgA antibody in mouse intestinal secretions. J Immunol Methods 1984;67:101-8.
26. Barclay WS, Callow KA, Sergeant M, Al-Nakib W. Evaluation of an enzyme-linked immunosorbent assay that measures rhinovirus-specific antibodies in human sera and nasal secretions. J Med Virol 1988;25:475-82.
27. Waldman RH, Stone J, Bergmann K-C, Khakoo R, Lazzell V, Jacknowitz A, et al. Secretory antibody following oral influenza immunization. Am J Med Sci 1986;292:367-71.
28. Lichtenstein LM, Norman PS, Winkenwerder WL. A single year of immunotherapy for ragweed hayfever: immunologic and clinical studies. Ann Intern Med 1971;75:663-71.
29. Morrison DF. Applied linear statistical methods. Englewood Cliffs (NJ): Prentice Hall; 1983. p. 407-12.
30. Patterson R, Grammer LC, Shaughnessy MA. Immunotherapy: parameters of assessment J Allergy Clin Immunol 1983;76:394-7.
31. Cooke RA, Barnard JH, Hebald S, Stall A. Serologic evidence of immunity with coexisting sensitization in a type of human allergy (hayfever). J Exp Med 1935;62:733-50.
32. Loveless MH. Immunological studies of pollinosis. IV. The relationship between thermostabile antibody in the circulation and clinical immunity. J Immunol 1943;47:1765-809.
33. Lichtenstein LM, Holtzman NA, Burnett LS. A quantitative in vitro study of the Chromatographic distribution and immunoglobulin characteristics of human blocking antibody. J Immunol 1968;101:317-24.
34. Daëron M, Malbec O, Latour S, Arock M, Fridman WH. Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors. J Clin Invest 1995:95:577-85.
35. Larsen GL, Wilson ML, Clark RAF, Behrens BL. The inflammatory reaction in the airways in an animal model of the late asthmatic response. Fed Proc 1982:46:105-12.
36. AAAI Board of Directors. Measurement of specific and nonspecific IgG4 levels as diagnostic and prognostic tests for clinical allergy. J Allergy Clin Immunol 1995;95:652-54.
37. Taudorf E, Laursen L. Lanner A, Björksten B, Dreborg S, Weeke B. Specific IgE, IgG1 and IgA antibody response to oral immunotherapy in birch pollinosis. J Allergy Clin Immunol 1989;83:589-94.
38. Nish WA, Charlesworth EN, Davis TL, Whisman BA, Valtieo S, Charlesworth MG. The effect of immunotherapy on the cutaneous late phase response to antigen. J Allergy Clin Immunol 1994:93:484-93.
39. Creticos PS, Van Metre TE, Mardiney MR, Rosenberg GL, Norman PS, Adkinson NF Jr. Dose response of IgE and IgG antibodies during ragweed immunotherapy. J Allergy Clin Immunol 1984;73:94-104.
40. Lichtenstein LM, Ishizaka K, Norman PS, Sobotka AK, Hill BM. IgE antibody measurements in ragweed hayfever: relationship to clinical severity and the results of immunotherapy. J Clin Invest 1973;52:472-82.
41. Yunginger JW, Gleich GJ. Seasonal changes in IgE antibodies and their relationship to IgG antibodies during immunotherapy for ragweed hayfever. J Clin Invest 1973;52:1268-75.
42. Norman PS, Winkenwerder WL, Lichtenstein LM. Maintenance immunotherapy in ragweed hay fever. J Allergy 1971;47:273-82.
43. Mestecky J. The common mucosal immune system and current strategies for induction of immune responses in external secretions. J Clin Immunol 1987;7:265-76.
44. Reed CE, Bubak D, Dunnette S, Blomgren J, Pfenning M, Wentz-Murtha P, et al. Ragweed-specific IgA in nasal lavage fluid of ragweed-sensitive allergic rhinitis patients: increase during the pollen season. Int Arch Allergy Appl Immunol 1991;94:275-7.
45. Abu-Ghazaleh RI, Fujisawa T, Mestecky J, Kyle RA, Gleich GJ. IgA-induced eosinophil degradation. J Immunol 1989;142:2393-400.
46. Franklin W, Lowell FC. Comparison of two dosages of ragweed extract in the treatment of pollenosis. JAMA 1967;201:915-7.
47. Van Metre TE, Adkinson NF, Amodie FJ, Sobotka AK, Lichtenstein LM, Mardiney ML, et al. A comparison of immunotherapy schedules for treatment of ragweed pollen hayfever. J Allergy Clin Immunol 1982;69:181-93.
48. Stewart GE II, Lockey RF. Systemic reactions from allergen immunotherapy. J Allergy Clin Immunol 1992;90:567-78.
49. Flanagan M, Wang C, Litwin A, Michael JG. Induction of an immune response in BDF1 mice by microencapsulated allergens following oral delivery [abstract]. J Allergy Clin Immunol 1994;93:252.